Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
platelet lysate (Regenexx)
- Development stage
- Unknown
- Lead developer
- Regenexx
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Epidural
01
Overview
Platelet lysate (PL) is an autologous biologic therapy developed by Regenexx, LLC, specifically for the treatment of lumbosacral radiculopathy (sciatica). It is an advanced derivative of platelet-rich plasma (PRP) produced by lysing (breaking open) the patient's own platelets to immediately release a high concentration of growth factors, cytokines, and exosomes. Unlike standard PRP, which contains intact platelets that release factors over time, PL provides an immediate anti-inflammatory effect, making it more suitable for use around sensitive nerve roots in the epidural space. The treatment is administered via image-guided epidural injection and is being evaluated as a regenerative alternative to corticosteroid injections.
- Brand names
- Regenexx-PL
- Other names
- PLautologous platelet lysateRegenexx Platelet Lysate
02
Targets
EGFR (Epidermal growth factor receptor)FGFR (Fibroblast growth factor receptor)IGF-1R (Insulin-like growth factor 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)TGFBR1VEGFR-1 (Vascular endothelial growth factor receptor 1)IGF-1 (Insulin-like growth factor 1)PDGF (Platelet-derived Growth Factor family)TGFB (GARP–latent transforming growth factor beta 1 complex)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on platelet lysate (Regenexx).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on platelet lysate (Regenexx).